肥満低換気症候群治療の世界市場 - 2022年～2029年

当レポートでは、世界の肥満低換気症候群治療市場について調査し、市場の概要とともに、治療別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 肥満低換気症候群治療市場の調査手法と範囲

第2章 肥満低換気症候群治療市場-市場の定義と概要

第3章 肥満低換気症候群治療市場-エグゼクティブサマリー

• 治療別、市場内訳
• エンドユーザー別、市場内訳
• 地域別、市場内訳

第4章 肥満低換気症候群治療市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 肥満低換気症候群治療市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 肥満低換気症候群治療市場-COVID-19分析

第7章 肥満低換気症候群治療市場-治療別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、治療別
• 市場魅力指数、治療別
  • 酸素療法
  • 非侵襲的人工呼吸
  • 薬物療法
  • その他

第8章 肥満低換気症候群治療市場-エンドユーザー別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、エンドユーザー別
  • 市場魅力指数、エンドユーザー別
• 病院
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• クリニック
• その他

第9章 肥満低換気症候群治療市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第10章 肥満低換気症候群治療市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第11章 肥満低換気症候群治療市場-企業プロファイル

• Avet Pharmaceuticals Inc.
• Accord Healthcare
• Nostrum Laboratories Inc.
• Lannett
• Strides Pharma Science Limited
• Xgen Pharmaceuticals Djb Inc.
• ResMed
• Koninklijke Philips N.V.
• Hikma Pharmaceuticals PLC

第12章 肥満低換気症候群治療市場-DataM

Market Overview

The global obesity hypoventilation syndrome treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Obesity hypoventilation syndrome (OHS) is a condition that causes low oxygen and high carbon dioxide levels in the blood in some obese people.

Market Dynamics

The factors influencing the global obesity hypoventilation syndrome treatment market are advancements in treatment options and the growing prevalence of obesity.

The advancement in treatment options is expected to drive the market growth in the forecast period

The mainstay of treatment for OHS is to provide breathing support, which is often accomplished through the use of CPAP or bilevel machines. These devices produce a pressurized airflow that prevents the upper airway from collapsing while sleeping. Finally, any treatment for obesity hypoventilation syndrome should address the underlying issues contributing to the disease. Because of the disease's dysfunctional breathing, the chemical levels in the blood become unbalanced. When carbon dioxide is not properly removed from the body, its levels rise, making the blood acidic. This causes a number of physiological changes in the body, some of which can be harmful.

Treatment can prevent drops in blood oxygen saturation, erythrocytosis (an increase in red blood cell count), pulmonary hypertension, and heart failure (cor pulmonale). Weight loss brings oxygen and carbon dioxide levels back to normal. CPAP or bilevel therapy, as well as other measures, can help to reduce the severity of these complications.

Moreover, Positive-airway pressure (PAP) therapy will certainly be required to treat sleep-related breathing disorders. Continuous positive airway pressure (CPAP) or noninvasive ventilation, most commonly in Bi-level PAP, are two types of PAP support (BPAP). These devices deliver air via a mask that one wears while sleeping or napping. The air is delivered at constant pressure when one breathes in and out through a CPAP machine. BPAP delivers higher pressure when one breathes in than when you breathe out. When OSA is severe and not controlled by PAP, a tracheostomy (neck surgery) may be required to ensure that OSA is adequately treated.

The limitations associated with obesity hypoventilation syndrome treatment are expected to hamper the market growth

Obesity hypoventilation syndrome is becoming more common in outpatient and inpatient respiratory clinics. Obesity hypoventilation syndrome has a number of negative health and social consequences. Unfortunately, when the syndrome is not recognized or misdiagnosed, the diagnosis and initiation of appropriate therapy are frequently delayed. Positive airway pressure therapy (PAP) is still the gold standard of care for controlling sleep-disordered breathing and improving awake blood gases in the vast majority of people. There is little evidence to support one mode of therapy over another. Daytime gas exchange can be improved using both continuous and bilevel therapy modes, with adherence to therapy being an important modifiable factor in treatment response. Compared to those with eucapnic sleep apnea who use CPAP, these individuals continue to have an increased risk of death, primarily due to cardiovascular events, despite adherence to therapy. Hence, the global obesity hypoventilation syndrome treatment market is expected to be hampered.

COVID-19 Impact Analysis

The COVID-19 pandemic has struck when the prevalence of overweight/obesity is rising in almost every country. People who are overweight or obese account for more than 20% of the population in almost every country today. To date, no country has seen a decrease in the number of people who are overweight or obese. Individuals with excess body fat, particularly visceral adipose tissue; obesity; major cardiometabolic problems, such as hypertension, cardiovascular disease, and type 2 diabetes (T2D); and a number of cancers have a strong link. Individuals with obesity's underlying metabolic and inflammatory factors play a significant role in developing severe lung diseases. Hence, the covid-19 is expected to positively impact the market growth.

Segment Analysis

Oxygen Therapy segment is expected to dominate the market growth

Oxygen therapy is a treatment that allows you to breathe in more oxygen. Supplemental oxygen is another name for it. It can only be obtained with a prescription from a physician. Oxygen therapy is a treatment that gives extra oxygen or supplemental oxygen. Oxygen therapy is commonly used in hospitals, but it can also be used at home. At home, a variety of devices are used to deliver oxygen. In addition to nocturnal bilevel PPV, approximately 50% of patients with OHS require oxygen therapy. However, in stable patients with obesity-related hypoventilation, breathing 100 percent oxygen may worsen hypercapnia due to a reduction in minute ventilation, resulting in alveolar hypoventilation and an increase in the volume of dead space-to-tidal volume ratio. As a result, oxygen therapy should be used with caution in morbidly obese patients.

Geographical Analysis

North America region is expected to hold the largest market share in the global obesity hypoventilation syndrome treatment market

Increasing disease prevalence increased R&D investment, and a well-developed healthcare sector in this region is expected to drive the market growth.

Obesity is a major health problem in the United States, resulting in various diseases. The adult obesity rate in the United States is now 42.4 percent, marking the first time the national rate has surpassed 40% and adding to the country's obesity crisis. Obesity is prevalent in the United States, with 37.9% of men and 41.1 percent of women classified as obese. Many companies are manufacturing drugs that are helpful in the treatment of obesity hypoventilation syndrome. For instance, Avet Pharmaceuticals Inc. a company based in United States that manufactuers Acetazolamide which is a carbonic anhydrase inhibitor that is used as a respiratory stimulant. The inhibition of the renal CA enzyme, which causes a decrease in serum bicarbonate and serum pH, is the traditional explanation for why acetazolamide acts as a respiratory stimulant.

Competitive Landscape

With mergers, collaborations, and product launches, the global obesity hypoventilation syndrome treatment market is moderately competitive. Some of the key players in the market are Accord Healthcare, Avet Pharmaceuticals Inc., Nostrum Laboratories Inc., Lannett, Strides Pharma Science Limited, XGen Pharmaceuticals DJB, Inc., ResMed, Koninklijke Philips N.V., Hikma Pharmaceuticals PLC

Avet Pharmaceuticals Inc.

Overview: Avet is a fast-growing specialty pharmaceutical company specializing in the acquisition, licensing, development, marketing, sale, and distribution of generic and legacy branded pharmaceutical products for the prescription drug market in the United States. Avet, which was founded in 2006, now sells a wide range of products in various pack sizes. Avet's products cover a wide range of therapeutic areas, including cardiovascular, metabolic, anti-infective, and pain management, to name a few.

Product Portfolio: Acetazolamide is a carbonic anhydrase inhibitor used as a respiratory stimulant. The inhibition of the renal CA enzyme, which causes a decrease in serum bicarbonate and serum pH, is the traditional explanation for why acetazolamide acts as a respiratory stimulant.

Why Purchase the Report?

Visualize the composition of the global obesity hypoventilation syndrome treatment market segmentation by treatment and end-user highlighting the key commercial assets and players.

Identify commercial opportunities in global obesity hypoventilation syndrome treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global obesity hypoventilation syndrome treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global obesity hypoventilation syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Obesity Hypoventilation Syndrome Treatment Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Obesity Hypoventilation Syndrome Treatment Market- Market Definition and Overview

3. Obesity Hypoventilation Syndrome Treatment Market- Executive Summary

• 3.1. Market Snippet By Treatment
• 3.2. Market Snippet By End User
• 3.3. Market Snippet By Region

4. Obesity Hypoventilation Syndrome Treatment Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The advancement in treatment options
  • 4.1.2. Restraints:
    • 4.1.2.1. The limitations associated with obesity hypoventilation syndrome treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Obesity Hypoventilation Syndrome Treatment Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Obesity Hypoventilation Syndrome Treatment Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Obesity Hypoventilation Syndrome Treatment Market-By Treatment

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
• 7.3. Market Attractiveness Index, By Treatment
  • 7.3.1. Oxygen Therapy*
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Noninvasive mechanical ventilation
    • 7.3.2.1. Continuous Positive Airway Pressure (CPAP)
    • 7.3.2.2. Bilevel Positive Airway Pressure (BiPAP)
  • 7.3.3. Pharmacotherapy
    • 7.3.3.1. Acetazolamide
    • 7.3.3.2. Almitrine
    • 7.3.3.3. Progesterone
  • 7.3.4. Other

8. Obesity Hypoventilation Syndrome Treatment Market- By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospital*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Clinics
• 8.4. Other

9. Obesity Hypoventilation Syndrome Treatment Market- By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Obesity Hypoventilation Syndrome Treatment Market- Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking

11. Obesity Hypoventilation Syndrome Treatment Market- Company Profiles

• 11.1. Avet Pharmaceuticals Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Accord Healthcare
• 11.3. Nostrum Laboratories Inc.
• 11.4. Lannett
• 11.5. Strides Pharma Science Limited
• 11.6. Xgen Pharmaceuticals Djb Inc.
• 11.7. ResMed
• 11.8. Koninklijke Philips N.V.
• 11.9. Hikma Pharmaceuticals PLC

LIST NOT EXHAUSTIVE

12. Obesity Hypoventilation Syndrome Treatment Market- DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us